Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer
WELCOME to
    GBC e - journal
      Editor-in-Chief, D. Roukos, MD, PhD
WEB
LAST UPDATE: April 24, 2012
    GBCNC Web Site
      Associate Editor: D. Trichopoulos, MD, PhD, Harvard/ U.S
FOCUS
2010
GBC
E JOURNAL
SERVICES
ARCHIVE
DOIs
REGISTER
    LOG IN
    NEW USER

SUBSCRIBE

NLM/NIH is a new subscriber to GBC

INDIVIDUALS
INSTITUTIONS/ LIBRARIES
SUBMIT A MANUSCRIPT
Call for papers
Instruction
Copyright
Conflict
REVIEWERS
Contact Us
Information
The Foundation for Hair Restoration specializes in hair transplant procedures for men and women

GBC
CURRENT ISSUE: 2012, (Apr)Vol. 11, Issue 2, pages 50-107
EDITORIAL

Transcriptome mapping: ER-binding sites dynamics reveal new strategy for breast cancer biomarkers
Despite thousands of enthusiastic biomarkers reports, therapeutic response prediction before therapy initiation still remains a daunting challenge. Revolutionary genome-wide mapping technologies (ChIP-seq) provide unprecedented ability for transcriptome analysis. With the dynamic of ER-binding sites that has more recently reported in  Nature , a new epoch of translational transcriptome mapping-based biomarkers has been launched.

Genome-based diagnostics and therapeutics in personalized cancer therapy: Can the challenges be overcome?
Although targeting cancer with antibodies and/or kinase inhibitors can improve oncological outcomes, resistance still remains a grand challenge. How could NGS technologies and systems computational biology advances result in overcoming resistance and therapeutic failure?

 
PERSPECTIVE

Science and technology: revealing genome networks for improving health
Breakthrough in genome-wide mapping technologies in concert with advanced systems and synthetic biology allow us now deeper insights into structural and functional genome and cells regulation. But how can these research advances can have practical medical implementations?

‘Sequence everything' strategy in the clinical cancer genome era
As we are shifting from research to clinical whole-genome sequencing and whole-exome sequencing for cancer clinical practice, which are the challenges and how can we overcome anticancer drugs resistance and therapeutic failure in the era of personalized cancer therapy?
Tumor heterogeneity-based personalized oncology
Next-generation sequencing technologies provide the power to detect most genetic mutations and epigenetic alterations driving cancer initiation and metastasis. Is such identification underlying each individual patient sufficient to reach personalized oncological therapy or further understanding of deregulated signalling pathways network and cellular dysfunction in cancer cells is essential for achieving pragmatic improvements in cancer treatment?
 
NEWS & VIEWS
 
REVIEW

Management of advanced non-clear cell renal carcinoma.
Renal cell carcinoma (RCC) comprises 2-3% of all malignancies. Approximately 90% of renal tumors are RCCs, and 15% of these are non-clear cell tumors, which include papillary, chromophobe, Bellini duct (collecting duct) and sarcomatoid tumors.

Solid cancer: Evaluating potential efficacy of epigenetic drugs.
Despite targeted cancer therapy, resistance, treatment failure, disease progression and cancer death rates are still high. Can epigenetic drugs added to current standard therapeutics improve oncological outcomes of patients with solid cancer?
GBC
PAST ISSUE
 
PERSPECTIVE
 
 
 
EDITORIAL
 
 
COMMENTARY
 
 
NEWS & VIEWS
Economic crisis and laparoscopic surgery.
REVIEW
BREAKTHROUGH PAPERS
Nature, Green, 2011
Cell, Hanahan, 2011
Science, Blaxter, 2010
Nat Rev Drug Discov, Garzon, 2010
Science, modENCODE Consortium, 2010
Cell, Ashworth, 2011
Nature, de Bono, 2010
Science, Chaffer, 2011
Nat Biotechnol, Kelly, 2010
Lancet, Maughan, 2011
N Engl J Med, Chapman, 2011
Nat Biotechnol, Feinberg, 2010
Nat Biotechnol, Portela, 2010
EMBO J, van Steensel, 2011
ΚΛΗΡΟΝΟΜΙΚΟΣ ΚΑΡΚΙΝΟΣ ΜΑΣΤΟΥ - ΩΟΘΗΚΗΣ
Ο ΑΛΓΟΡΙΘΜΟΣ ΤΟΥ ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΙΩΑΝΝΙΝΩΝ

Ολοκληρωμένο, 4-βημάτων μοντέλο για εξατομικευμένη κλινική απόφαση :

    •  BRCA θετικό τεστ
    •  BRCA αρνητικό τεστ         
Πληροφορίες

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655 ..

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Search only trustworthy HONcode health websites:

last update: 24 April 2012